Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Viktrup

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
Health and Quality of Life Outcomes|November 16, 2010
Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studiesMallik Angalakuditi, Rita F Seifert, Risa P Hayes, et al.
BJU International|August 14, 2013
Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunctionGerald Brock, Gregory Broderick, Claus G Roehrborn, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 28, 2014
Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and KoreaMasayuki Takeda, Osamu Yokoyama, Sung Won Lee, et al.
World Journal of Urology|February 8, 2014
Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studiesMatthias Oelke, Jeffrey P Weiss, Charalampos Mamoulakis, et al.
Current Medical Research and Opinion|January 30, 2007
A retrospective pooled analysis of duloxetine safety in 23,983 subjectsJames Gahimer, Joachim Wernicke, Ilker Yalcin, et al.
Patient Preference and Adherence|April 3, 2025
Patient Preferences for Episodic Migraine Medications: A Discrete Choice Experiment of Self-Injectable Versus Oral Treatments Targeting Calcitonin Gene-Related Peptide PathwayChiara Whichello, Lars Viktrup, Oralee J Varnado, et al.
The Journal of Sexual Medicine|January 26, 2013
Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind studyFrançois Giuliano, Matthias Oelke, Andreas Jungwirth, et al.
European Urology|October 11, 2014
Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trialsChristopher R Chapple, Claus G Roehrborn, Kevin McVary, et al.
Pain|May 31, 2019
Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safetyMartin Schmelz, Patrick Mantyh, Anne-Marie Malfait, et al.
Urology|July 24, 2013
Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studiesHartmut Porst, Matthias Oelke, Evan R Goldfischer, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Health and Quality of Life Outcomes|November 16, 2010
Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studiesMallik Angalakuditi, Rita F Seifert, Risa P Hayes, et al.
BJU International|August 14, 2013
Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunctionGerald Brock, Gregory Broderick, Claus G Roehrborn, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 28, 2014
Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and KoreaMasayuki Takeda, Osamu Yokoyama, Sung Won Lee, et al.
World Journal of Urology|February 8, 2014
Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studiesMatthias Oelke, Jeffrey P Weiss, Charalampos Mamoulakis, et al.
Current Medical Research and Opinion|January 30, 2007
A retrospective pooled analysis of duloxetine safety in 23,983 subjectsJames Gahimer, Joachim Wernicke, Ilker Yalcin, et al.
Patient Preference and Adherence|April 3, 2025
Patient Preferences for Episodic Migraine Medications: A Discrete Choice Experiment of Self-Injectable Versus Oral Treatments Targeting Calcitonin Gene-Related Peptide PathwayChiara Whichello, Lars Viktrup, Oralee J Varnado, et al.
The Journal of Sexual Medicine|January 26, 2013
Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind studyFrançois Giuliano, Matthias Oelke, Andreas Jungwirth, et al.
European Urology|October 11, 2014
Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trialsChristopher R Chapple, Claus G Roehrborn, Kevin McVary, et al.
Pain|May 31, 2019
Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safetyMartin Schmelz, Patrick Mantyh, Anne-Marie Malfait, et al.
Urology|July 24, 2013
Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studiesHartmut Porst, Matthias Oelke, Evan R Goldfischer, et al.
Pageof 12